GlobalData
GlobalData

Press Release

North Americans are the least informed about GDPR in Pharma

North Americans were the least likely to say that they feel informed about the requirements of the General Data Protection Regulation (GDPR) out of those surveyed in the global pharmaceuticals industry, according to GlobalData, a leading data and analytics company. The company’s latest report: ‘GDPR in the Healthcare Industry’ states that only 54% of North […]
Read more

P&G needs to mitigate impact of growing production costs to drive earnings forward despite showing positive net sales growth in Q4 results

‘‘P&G’s fourth quarter results indicate positive net sales growth of 3%. However an increase in costs of 9% in its supply chain has served to reduce net earnings compared with the same period in 2017. The company will need to reduce its supply and manufacturing overheads or consider increasing its prices to mitigate the impact of growing commodity costs experienced across the consumer goods landscape on its bottom line.
Read more

GDPR has had a greater impact on R&D in healthcare compared to other industries

R&D departments in healthcare organisations have felt a significantly higher impact due to the General Data Protection Regulation (GDPR) than in other sectors, according to GlobalData, a leading data and analytics company. The company’s latest report: ‘GDPR in the Healthcare Industry’ finds that, whilst most business departments have been affected similarly regardless of which sector […]
Read more

Card infrastructure is showing its age

Following the news (Thursday 2 August) that NatWest debit cards were unusable for two hours this afternoon, Sam Murrant, Senior Payments Analyst at GlobalData, a leading data and analytics company, offers his view on the future of card-based payments: “The payments industry is increasingly moving towards an assumption that we will pay for everything electronically […]
Read more

Launch of Aimovig signals the start of a boom in the European migraine market

Following the launch of Novartis’ anti-migraine drug, Aimovig, in Europe, Rahael Maladwala, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view on the potential growth of the market: “The calcitonin gene-related peptide (CGRP) monoclonal antibody class has generated significant excitement among headache specialists since posting promising efficacy results in early stage […]
Read more

Takeda will be looking to Shire’s drug pipeline to bolster future sales after disappointing Q1 results

Following the announcement of a significant dip in first-quarter operating profit for Takeda, Thomas Moore, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers his view on the company’s future: “Takeda’s first-quarter operating profits took a 49% hit year-on-year, and represent the weakest first quarter profit in the last three years. Looking […]
Read more

Merck KGaA looking to become a key player in the multiple sclerosis market as the FDA accept Mavenclad for review

Following the announcement that the FDA have accepted Merck KGaA’s resubmitted application for Mavenclad, seven years after the original application, Rahael Maladwala, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view on the company’s current progress: “Merck KGaA have placed themselves in a strong position in the multiple sclerosis market with […]
Read more

Cash is not dead yet

Following the announcement (Friday 27 July) that there will be a review for cash access after a surge in digital payments, Sam Murrant, Senior Payments Analyst at GlobalData, a leading data and analytics company, offers his view on the future of cash payments: “Cash in the UK is by no means as dead or dying […]
Read more

Quorn’s investments in vegan foods is further evidence that veganism successfully captures consumers’ secondary dieting concerns

Following yesterday’s news (Monday 23 July) that Quorn is to invest a further £7m in R&D to create more vegan products, Will Grimwade, Associate Analyst at GlobalData, a leading data and analytics company, suggests this is indicative of a wider trend: “Quorn’s decision to continue to orientate their new products towards the vegan market is […]
Read more

Overall global risk remains flat in Q1 2018

According to the latest results from the ‘Country Risk Index’ (GCRI) compiled by GlobalData, a leading data and analytics company, the overall global risk score remained flat at 40.1 out of 100 in Q1 2018 – unchanged from Q3 2017, following a reduction from 40.4 in Q2 2017. The company’s index is a unique country […]
Read more
1 46 47 48 49 50 61